Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled study of QX004N in adults with moderate-to-severe plaque psoriasis
CTR20232772Phase 2Active
- Sponsor
- Qiansin
- Start
- Sep 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of QX004N in plaque psoriasis, sponsored by Qiansin. Started Sep 2023; status: active.
02
Drugs
QX004N
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on CTR20232772.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232772.